Aarti Drugs share news, announcements and annual reports
NSE: AARTIDRUGSBSE: 524348Pharmaceuticals & BiotechnologySmall Cap
Aarti Drugs Limited · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Sep 1993 on BSE, Sep 2003 on NSE
Last close ₹435.20down ₹13.80 (3.07%)BSE ₹435.70
Share price at the NSE close on 30 Oct 2026. Previous close ₹449.00.
30 Oct: open ₹444.00, high ₹449.00, low ₹432.50
52-week range of traded prices to 30 Oct 2026
₹318.95Low, 30 Mar 2026₹534.00High, 10 Nov 2025
- Next results date: the board meets on 3 Nov 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹3,972 Cr930th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 20.78
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 2.56
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.46%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 13.1%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 12.4%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.37
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 2,91,56330.3% delivered
Aarti Drugs orders, deals and press releases
55 filed, newest first. Page 2 of 2.
Nov 2016
Aug 2016
12 Aug · Business
May 2016
5 May · Business
Feb 2016
5 Feb · Business
Aug 2008
6 Aug · Business
Aarti Drugs Ltd. has informed the Exchange that at the meeting of the Board of Directors of the Company, held on August 6, 2008, the following decision has been taken subject to the approval of the Company at its Extra-Ordinary General Meeting to be held on September 5, 2008. Pursuant to the provisions of Section 81(1A) and all other applicable provisions of the Companies Act, 1956 ( including any statutory modifications or re-enactment thereof, for the time being in force) and pursuant to the provisions of Chapter XIII of the Securities and Exchange Board of India ( Disclosure and Investor Protection) Guidelines 2000, the Company shall issue not exceeding 6,00,000 convertible warrants, on preferential basis, to the Promoters and Promoter Group Companies, subject to the shareholder's approval, as aforesaid. Each of the said warrants would entitle the holder(s) thereof to apply for and obtain allotment of one Equity share of Rs. 10/- each thereof on a future date not exceeding 18 months from the date of allotment of warrant as per the Chapter XIII of the Securities and Exchange Board of India (Disclosure and Investors Protection) Guidelines 2000 at an issue price of Rs.52.60 ps. per share. The issue price for the warrants is fixed at 10% of the issue price of the resulting shares upon conversion. The "Relevant Date" for the purpose of determining the said issue price for the Preferential Issue of the warrants and resultant shares as aforesaid is August 6, 2008 i.e. 30 days prior to the date of the Extra-ordinary General Meeting as aforesaid at which the said preferential issue will be considered for approval in terms of Chapter XIII of the Securities and Exchange Board of India (Disclosure and Investor Protection) Guidelines 2000.